Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 4/20 | 0.36 |
| ▸ | CYP17A1 | P05093 | 3/20 | 0.35 |
| ▸ | CTSL | P07711 | 2/20 | 0.35 |
| ▸ | CTSB | P07858 | 2/20 | 0.35 |
| ▸ | CTSS | P25774 | 2/20 | 0.35 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.33 |
| ▸ | CHKA | P35790 | 1/20 | 0.33 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.32 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.32 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4597232 | 0.78 | CYP17A1 (0.38) | F2CYP17A1CHRM5CHKAGPR119 | |
| SCHEMBL481946 | 0.77 | PAX8 (0.49) | F2CYP17A1CHRM5CHKAGPR119 | |
| SCHEMBL15948302 | 0.76 | F2 (0.38) | F2CYP17A1CHRM5CHKAGPR119 | |
| Potassium SCHEMBL30601778 | 0.76 | PAX8 (0.48) | F2CYP17A1CHRM5CHKAGPR119 | |
| SCHEMBL30073325 | 0.73 | F2 (0.47) | F2CHRM5PAX8 | |
| SCHEMBL9269882 | 0.73 | KDM4E (0.42) | CYP17A1CHRM5CHKA | |
| SCHEMBL7328872 | 0.72 | MT-CO2 (0.41) | F2CYP17A1CHRM5CHKALMNA | |
| SCHEMBL22171271 | 0.72 | F2 (0.43) | F2CYP17A1LMNASSTR4CYP19A1 | |
| SCHEMBL19317380 | 0.71 | F2 (0.50) | F2CYP17A1GPR119LMNASSTR4 | |
| SCHEMBL3362088 | 0.70 | F2 (0.38) | F2CYP17A1LMNACYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1122242-B1 | CYANOPHENYL DERIVATIVES | ASTELLAS PHARMA INC (JP) | 2008-01-16 | — | — | EP | disclosed |
| US-20040010037-A1 | Cyanophenyl derivative | YAMANOUCHI PHARMACEUTICAL CO., LTD. | 2004-01-15 | — | — | US | disclosed |
| US-6673799-B1 | INHIBITS BINDING TO ANDROGEN RECEPTOR; ANTIANDROGEN | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2004-01-06 | — | — | US | disclosed |
| EP-1122242-A1 | CYANOPHENYL DERIVATIVES | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2001-08-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040010037-A1 | Cyanophenyl derivative | BPHL, AR, KLK3 | F2 4613/4885CYP17A1 8/4885CTSL 398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.